Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) reported Q4 and full‑year 2025 results for the period ended December 31, 2025. Q4 revenue was $44.6M (up 14% YoY) and FY revenue was $160.0M. Non‑GAAP gross margin improved to 40% in Q4 and FY 2025. The company completed the sale of short‑read assets for $48.1M net cash and ended the year with $279.5M in cash, cash equivalents, and investments.
Notable operational items included record consumables revenue, strong Vega system placements, reduced non‑GAAP operating expenses, and a GAAP net loss of $546.4M for FY 2025.
PacBio (NASDAQ: PACB) is joining the iHope global rare-disease genomics network as its first long-read sequencing partner to integrate HiFi long-read whole-genome sequencing.
iHope supports more than 1,000 patients annually across 25 clinical sites in 14 countries. Integration is expected to begin in early 2026 and aims to improve detection of challenging variants and support future precision-therapeutic research.
PacBio (NASDAQ: PACB) completed the sale of select short-read sequencing intellectual property and related assets to Illumina, closing January 30, 2026. PacBio received $48.1 million in net cash proceeds, Illumina assumed certain liabilities, and granted PacBio a non-exclusive license back to specified intellectual property.
PacBio said the transaction sharpens its focus on long-read sequencing, accelerates SPRQ-Nx chemistry development, and strengthens the company balance sheet.
PacBio (NASDAQ: PACB) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. A quarterly conference call and webcast will be held at 5:00 PM Eastern Time (2:00 PM Pacific) and will be accessible via PacBio's investor website.
Investors can listen live via the webcast or by phone: toll-free 1-888-349-0136 or international 1-412-317-0459. A replay will be available on the investor site after the call.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare to apply HiFi long‑read whole‑genome sequencing to support individualized antisense oligonucleotide (ASO) therapies for ultra‑rare genetic diseases. PacBio will donate sequencing reagents and provide scientific resources to enable variant phasing, structural variant detection, repeat expansion resolution, and regulatory‑grade molecular characterization to inform ASO target identification, design feasibility, and regulatory documentation. The collaboration aims to reduce sequential tests, accelerate target validation, and strengthen end‑to‑end genomics‑driven therapy development for n‑of‑1 patients.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 that a UW Medicine and Seattle Children’s research team will use HiFi whole-genome sequencing on PacBio Revio with SPRQ-Nx chemistry as a first-line approach to investigate Sudden Unexplained Death in Childhood (SUDC). The study will sequence trios from 200 families (child plus parents), prioritize long-read HiFi data for comprehensive variant detection, and join the HiFi Solves Global Consortium. The approach aims to simplify workflows for challenging inputs (post-mortem tissue, newborn dried blood spots) and to increase diagnostic yield by resolving structural variants, tandem repeats, and by identifying de novo versus inherited contributors to risk. PacBio provides in-kind support and the project is backed by the SUDC Foundation.
PacBio (NASDAQ: PACB) reported preliminary unaudited revenue of $44.6M for Q4 2025 (+14% YoY) and $160.0M for full year 2025 (+4% YoY).
Q4 drivers included higher Revio and Vega shipments and a record $21.6M in consumables revenue. Instrument revenue declined to $17.3M in Q4 and $53.8M for 2025 versus prior-year instrument revenue of $65.8M. Service and other revenue rose to $5.7M in Q4 and $24.3M for 2025.
System placements: Revio 21 in Q4 (61 for 2025) and Vega 42 in Q4 (140 for 2025). Ending cash, cash equivalents, and investments were about $279.5M. Results are preliminary and expected to be finalized in the 2025 Form 10-K and a February earnings call.
PacBio (NASDAQ: PACB) and UC Davis researchers introduced CiFi, a community-developed method that combines multi-contact chromatin conformation capture (3C) with PacBio HiFi long-read sequencing to produce chromosome-scale, haplotype-resolved assemblies from a single Revio sequencing run.
CiFi generates long, concatemeric HiFi reads that capture multiple chromatin interactions per molecule, improving mapping in repetitive regions, enabling multi-contact resolution, and reducing input material, libraries, and sequencing runs. A Nature Communications publication and demonstration on prairie and meadow vole produced uncurated assemblies with scaffold N50 values exceeding 100 million base pairs and telomeric sequence at many scaffold ends.
PacBio (NASDAQ: PACB) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT (1:30 PM ET) in San Francisco.
A live webcast will be available on the company investor site and a replay will be posted for at least 30 days after the event.
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.